The A Allele of the rs1990760 Polymorphism in the *IFIH1* Gene Is Associated with Protection for Arterial Hypertension in Type 1 Diabetic Patients and with Expression of This Gene in Human Mononuclear Cells

Ana P. Bouças¹², Letícia A. Brondani¹², Bianca M. Souza¹², Natália E. Lemos², Fernanda S. de Oliveira¹, Luis H. Canani², Daisy Crispim¹²

¹ Laboratory of Biology of Human Pancreatic Islet, Endocrinology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; ² Postgraduate Program in Medical Sciences, Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

**Abstract**

Background: The rs1990760 polymorphism of interferon induced with helicase C domain 1 (*IFIH1*) has been associated with type 1 diabetes mellitus (T1DM). Here, we investigated whether this polymorphism is associated with T1DM or its clinical characteristics in a Brazilian population, and if *IFIH1* gene expression in mononuclear cells from T1DM patients differs according to the genotypes of this polymorphism. A meta-analysis was also conducted to evaluate if the rs1990760 polymorphism is associated with T1DM.

Methods: Frequencies of the rs1990760 polymorphism were analyzed in 527 T1DM patients and in 517 healthy subjects. *IFIH1* gene expressions according to genotypes were measured in a sub-sample of 26 T1DM patients by quantitative real-time PCR.

Results: Our data show the association of the A allele with risk to T1DM under a dominant model of inheritance [odds ratio (OR) = 1.421, *P* = 0.037], adjusting for ethnicity. The meta-analysis revealed significant association between the rs199760A allele and risk for T1DM for all analyzed inheritance models. Surprisingly, T1DM patients carrying the A allele showed lower levels of systolic (*P* = 0.001) and diastolic (*P* = 1 × 10⁻¹⁹) blood pressures as compared to G/G carriers. Furthermore, the A/A genotype seems to be associated with protection to arterial hypertension (AH) after adjustment for covariates (OR = 0.339, *P* = 0.019). *IFIH1* gene expression in mononuclear cells from 26 T1DM patients did not differ among genotypes (*P* = 0.274). Nevertheless, *IFIH1* gene expression was increased in mononuclear cells from T1DM patients with AH as compared with T1DM patients without AH (6.7 (1.7–2.0) arbitrary units; *P* = 0.036). The association with blood pressures and AH was not observed in patients with type 2 diabetes mellitus.

Conclusions: Our results indicate that the rs1990760 polymorphism is associated with T1DM. Interestingly, the rs1990760 A allele seems to be associated with protection for AH in T1DM patients. Further studies are needed to confirm the association with AH.

Citation: Bouças AP, Brondani LA, Souza BM, Lemos NE, de Oliveira FS, et al. (2013) The A Allele of the rs1990760 Polymorphism in the *IFIH1* Gene Is Associated with Protection for Arterial Hypertension in Type 1 Diabetic Patients and with Expression of This Gene in Human Mononuclear Cells. PLoS ONE 8(12): e83451. doi:10.1371/journal.pone.0083451

**Introduction**

Type 1 diabetes mellitus (T1DM), which accounts for 5–10% of those with diabetes, results from a cellular-mediated autoimmune destruction of the pancreatic beta-cells, which renders patients insulin-dependent for life [1]. The triggering of autoimmunity against beta-cells is probably caused by environmental factors acting in combination with a predisposing genetic background [2,3]. The major susceptibility locus maps to the HLA class II genes at chromosome 6p21 and accounts for up to 30–50% of the genetic risk for this disease [1,4]. Other non-HLA loci have smaller effects on disease risk compared to HLA, and include the *insulin* gene, the *CTLA4* gene, the *PTPN22* gene, the *IL2RA* gene, and the interferon induced with helicase C domain 1 (*IFIH1*) gene [4].

The hypothesis that viruses may be one of the environmental factors explaining the surprising increase in T1DM incidence during recent decades is strengthened by variations of T1DM incidence from one country to another and from a season to another, as well as by observations relative to the association...
between immigration and disease development [5]. Epidemiological, experimental and clinical data indicate that the prime viral candidates for causing T1DM in human are enteroviruses, such as Coxsackievirus B (CV-B) [5,6,7]. CV-B4 is the most common enterovirus found in pre-diabetic and diabetic subjects [7]. One CV-B4 strain isolated from the pancreas of a deceased diabetic child was able to induce diabetes in susceptible mice [8]. Moreover, CV-B4 was identified in the pancreatic tissue from three of six patients with T1DM [9], and it was capable of infecting human islet in vitro, impairing glucose-stimulated insulin secretion [10]. The pathogenic role of enteroviruses in T1DM seems to involve damage to beta-cells and local induction of proinflammatory mediators [11].

The immune response to virus infection begins with the recognition of pathogen-associated molecular patterns (PAMPs) as “nonself” signatures. This recognition occurs through host pattern recognition receptors (PRRs), and triggers intracellular signaling events that induce innate immunity, the front line of defense against microbial infection. PRRs are evolutionary conserved germ-line-encoded proteins and include Toll-like receptors (TLRs), retinoic acid-inducible I (RIG-I-like receptors (RIG-I and IFIH1 receptors) and nucleotide-binding oligomerization domain-like receptor (NLR) [12]. These PRRs recognize specific PAMPs in different cellular compartments, such as the plasma membrane, the endosomes or the cytoplasm, and induce the expression of proinflammatory cytokines, chemokines and co-stimulatory molecules which will eliminate the pathogens and activate pathogen-specific adaptive immune responses [12,13].

The IFIH1 gene, also known as melanoma differentiation-associated gene 5 (MDA5), is a functional candidate for T1DM because it encodes a cytosolic receptor that play a major role in the recognition of internal double-stranded RNA (dsRNA), an intermediate nucleic acid generated during the life cycle of most viruses [12,14], suggesting a potential role in the infectious etiology of T1DM and providing a link between viral infections and this disease. In fact, some studies have demonstrated the association of a non-synonymous polymorphism rs1990760 G/A (Ala946Thr) in exon 15 of the IFIH1 gene with T1DM in more than one population [15,16,17]. Therefore, the present study investigated whether the IFIH1 rs1990760 polymorphism is associated with T1DM or its clinical and laboratory characteristics in a Southeast Brazilian population, and if the IFIH1 gene expression in mononuclear cells from T1DM patients differs according to the different genotypes of this polymorphism. Moreover, a meta-analysis was conducted to attempt determining if the IFIH1 rs1990760 polymorphism is associated with T1DM.

Methods

Case-control Study and Analysis of the IFIH1 Gene Expression

Ethical approval of the research protocol. The information obtained from the study did not influence patients’ diagnosis or treatment. The study protocol was approved by Ethic Committee in Research from Hospital de Clínicas de Porto Alegre and all patients and nondiabetic subjects provided informed consent in writing. All clinical investigation has been conducted according to the principles expressed in the Declaration of Helsinki.

Subjects and phenotype measurements. This was a case-control study designed to investigate whether the IFIH1 rs1990760 polymorphism is associated with T1DM. The diabetic sample comprised 327 unrelated patients from the outpatient clinic at the Hospital de Clínicas de Porto Alegre (Rio Grande do Sul, Brazil). Patients were considered to have T1DM if they had been diagnosed with hyperglycemia before the age of 30 years, required insulin for glycemic control within 1 year of diagnosis, and this treatment could not be interrupted thereafter. The nondiabetic sample comprised 517 healthy blood donors who did not have diabetes mellitus or family history for this disease (mean age = 44.0±7.8; male = 55.0%). Additionally, to evaluate whether any association found between clinical characteristics of T1DM and the IFIH1 rs1990760 polymorphism could be replicated in a non-autoimmune diabetes context, we also analyzed 725 patients with type 2 diabetes mellitus (T2DM) from the same hospital [18]. T2DM was diagnosed according to the ADA guidelines [1], and clinical and laboratory characteristics of these patients can be found in Table S1 in File S1. The ethnic group was defined on the basis of self-classification, and the ethnic proportion was similar between the samples: 16.1% of black in T1DM group and 19.8% of black subjects in the nondiabetic group (P = 0.110).

A standard questionnaire was used to collect information on age, age at DM diagnosis, and drug treatment and all patients underwent physical and laboratory evaluations. They were weighed unshod, wearing light outdoor clothes and their height was measured. Body mass index (BMI) was calculated as weight (kg)/height square (meters). Blood pressure (BP) was measured by a trained researcher, with a mercury sphygmomanometer on the left arm, using an appropriated cuff size, in a sitting position, after a 5-min rest. The mean of two measurements taken 1 min apart was used to calculate systolic and diastolic BP. Arterial hypertension (AH) was defined as BP levels higher than 140/90 mmHg at initial visit and at two follow-up visits within 1 month of the initial visit, or if the presence of AH was registered on medical records. Assessment of diabetic retinopathy (DR) was performed in all patients by an experienced opthalmologist using fundoscopy through dilated pupils. DR was classified using the scale developed by the Global Diabetic Retinopathy Group [19]. For the purpose of this study, patients were grouped according to the presence or absence of any degree of DR. Diagnosis of diabetic nephropathy (DN) was based on the albumin excretion rate (AER) in at least two out of three consecutive 24-h timed or random spot sterile urine collections in a 6-month period. Patients were classified as having normoalbuminuria (AER <30 μg/24 h or <17 mg/l), microalbuminuria (AER 30–299 μg/24 h or 17–173 mg/l) or macroalbuminuria (AER >300 μg/24 h or >174 mg/l) [20].

Serum and plasma samples were taken after a 12 hours fasting for laboratory analyses. Plasma glucose levels were determined using the glucose oxidase method. Creatinine levels were determined using the Jaffe reaction. Glycated hemoglobin (HbA1c) measurements were performed by different methods and results were traceable to the DCCT method by off-line calibration or through conversion formulae [21]. Total plasma cholesterol, HDL cholesterol and triglycerides were assayed using enzymatic methods. Urinary albumin was measured by immunoturbidimetry (Microalbumin; Ames-Bayer, Tarrytown NY), and the intra- and interassay coefficients of variation in our laboratory were both <6% [22].

Genotyping. DNA was extracted from peripheral blood leukocytes using a standardized salting-out procedure. The IFIH1 rs1990760 (G/A) polymorphism was genotyped using primers and probes contained in the Human Custom TaqMan Genotyping Assay 20× (Assays-By-Design Service; Life Technologies, Foster City, CA). Sequences of primers and probes were: 5’-ACCATT-TATTTGATAGTGCAACC-3’ (forward); 5’-CTCCAT-GATGATTCTTTCCCTTGATACCT-3’ (reverse); 5’-AAAGAGAAACAAAGCAGCTG-3’ (VIC; specific to the G allele) and 5’-AAAGAGAAACAAAGCAGCTG-3’ (FAM, specific to the A
alle). Reactions were conducted in 96-well plates, in a total 5 µl volume using 2 ng of genomic DNA, TaqMan Genotyping Master Mix 1x (Life Technologies) and Custom TaqMan Genotyping Assay 1x. The plates were then positioned in a thermal cycler (7500 Fast Real-Time PCR System; Life Technologies) and heated for 10 min at 95°C, followed by 50 cycles of 95°C for 15 s and 63°C for 1 min. The genotyping success rate was better than 95%, with a calculated error rate based on PCR duplicates of less than 1%.

Isolation of mononuclear cells from peripheral blood of patients with T1DM and RNA extraction. Samples of 10 ml peripheral blood were collected from a sub-sample of 26 T1DM patients belonging to our case-control study. Immediately after collecting the samples, an aliquot of 2 ml of blood was mixed with an equal volume of PBS. Then, total mononuclear cells were isolated from blood by density gradient centrifugation using Ficoll-Paque™ plus reagent (GE HealthCare, Uppsala, Sweden). Isolated mononuclear cells were stored at −80°C until RNA extractions.

Total RNA was extracted from mononuclear cells using the RNaseasy Mini kit (Qiagen, Hilden, Germany). The concentration and quality of total RNA samples were assessed using a NanoDrop 2000 spectrophotometer (Thermo Scientific Inc., Newark, DE). Only RNA samples with adequate purity ratios (A260/A280 = 1.9–2.1) were used for subsequent analyses [23]. In addition, RNA integrity and purity were also checked on agarose gel containing GelRed Nucleic Acid Gel Stain (Biotium Inc., Hayward, CA).

Quantification of IFIH1 gene expression by Real-Time PCR. Real-Time PCR was performed in two separate reactions: first, RNA was reverse transcribed into cDNA, then cDNA was amplified by quantitative real-time PCR (RT-qPCR). Reverse transcription of 1 µg of RNA into cDNA was carried out using the High Capacity cDNA Reverse Transcription Kit (Life Technologies), following the manufacturer’s protocol for oligo (dT) method.

RT-qPCR experiments were performed in a Vi™ 7 Real-Time PCR System (Life Technologies). Experiments were performed by real-time monitoring of the increase in fluorescence of SYBER® Green dye [24]. Primers for the target (IFIH1) and reference (GAPDH) genes were: IFIH1: 5’-ATG-GAAAAAAAAACGTGCAAGA-3’ (forward), IFIH1: 5’-GTCATTCCTCCTAAAAGTGTCTGGACAA-3’ (reverse), GAPDH: 5’-ACCCACCTCCTCACCTTTT-3’ (forward) and GAPDH: 5’-CTCCTTTTGCTCCTTGAGG-3’ (reverse). PCR reactions were performed using 5 µl of 2x Fast SYBER® Green Master Mix (Life Technologies), 0.5 µl (0.5 ng/µl) of forward and reverse primers for IFIH1 or GAPDH, and 0.5 µl of cDNA template (1 µg/µl), in a total volume of 10 µl. Each sample was assayed in triplicate and a negative control was included in each experiment. The thermocycling conditions for these genes were as follows: an initial cycle of 95°C for 20 s, followed by 50 cycles of 95°C for 5 s and 60°C for 1 min. RT-qPCR specificity was determined using melting curve analyses and all primers generated amplicons that produced a single sharp peak during the analyses.

Quantification of the IFIH1 mRNA was performed using the relative standard curve method [25,26], and the GAPDH gene as the reference gene. Relative standard curves were generated for both target and reference genes by preparing serial dilutions of the same cDNA sample with a known relative quantity. Then, relative amounts of each IFIH1 cDNA sample were obtained by normalizing their signals by those of GAPDH gene, and are presented as arbitrary units (AU).

Statistical analyses. Allelic frequencies were determined by gene counting, and departures from the Hardy–Weinberg equilibrium (HWE) were verified using the χ²-test. Allele and genotype frequencies were compared between groups of patients using χ²-tests. Clinical and laboratory characteristics and mRNA abundance were compared between groups by using unpaired Student’s t-test, One-way ANOVA or χ², as appropriate. Variables with normal distribution are presented as mean ± SD or percentage. Variables with skewed distribution were log-transformed before analyses and are presented as median (minimum-maximum values). The magnitude of associations between rs1990760 genotypes and T1DM or its categorical clinical characteristics were estimated using OR (95% CI). Multivariate logistic regression analyses were performed to assess the independent association of the rs1990760 polymorphisms with T1DM or its categorical clinical characteristics and to control for possible confounding factors whenever a statistically significant association was detected by univariate analyses.
genetic inheritance models: (1) allele contrast; (2) additive model; (3) recessive model and (4) dominant model [29,30]. Heterogeneity was tested using a $\chi^2$-based Cochran’s $Q$ statistic and inconsistency was tested using the $I^2$ metric. Heterogeneity was considered statistically significant at $P < 0.10$ for the $Q$ statistic and $I^2 > 50\%$ [31,32]. Since no significant heterogeneity was found, the fixed effect model (FEM) was used to calculate OR (95% CI) for each individual study and for the pooled effect. Risk of publication bias was assessed using funnel plot graphics, analyzed both visually and with the Begg and Egger test [33]. $P$ values $<0.10$ were considered indicative of statistically significant publication bias. All statistical analyses were performed using Stata 11.0 software (StataCorp, College Station, TX, USA).

Results

Sample Description

The main clinical and laboratory characteristics of the 527 T1DM patients belonging to the present study were as follows: mean age was 33.6±11.8 years; mean age at T1DM diagnosis was 17.4±10.2 years; mean HbA1c was 8.7±4.1%; and mean BMI was 24.7±4.3 kg/m². Males comprised 48.0% of the sample, 16.1% were black, 28% of all patients had AH, 45.1% had some degree of DR, and 35.2% had some degree of DN.

Study of the Association between the IFIH1 rs1990760 (G/A) Polymorphism and Type 1 Diabetes Mellitus or its Clinical and Laboratory Characteristics

Genotype and allele frequencies of the rs1990760 (G/A) polymorphism in T1DM patients and nondiabetic subjects are depicted in Table 1. The frequency of the A allele was 29.4% in white subjects and 6.3% in black subjects ($P < 0.001$). Neither genotype nor allele frequencies of the rs1990760 polymorphism differed statistically between T1DM patients and nondiabetic subjects ($P = 0.139$ and $P = 0.129$, respectively), and all genotypes were in agreement with those predicted by the HWE in the two samples ($P > 0.05$). After adjustment for ethnicity, the A allele showed only a trend towards association with T1DM (A/G genotype: OR = 1.403, $P = 0.058$; A/A genotype: OR = 1.453, $P = 0.061$). However, the presence of the A allele was significantly associated with risk to T1DM under a dominant model of inheritance, adjusting for ethnicity (OR = 1.421, $P = 0.037$) (Table 1). Of note, after the exclusion of black patients from the sample, the presence of the A allele was significantly associated with risk to T1DM in white subjects under a dominant model of inheritance (OR = 1.381, 95% CI 1.003–1.903; $P = 0.048$).

In order to determine if the rs1990760 polymorphism influenced the severity of T1DM, we re-analyzed the data only including those patients with early-onset of T1DM (age at diagnosis <17 years) [16]. The frequency of the A allele also was increased in early-onset T1DM patients as compared to nondiabetic subjects, although this comparison did not reach
formal statistical significance (82.3% vs. 76.5%, respectively; P = 0.064 for the dominant model), probably due to the smaller sample size.

Clinical and laboratory characteristics of T1DM patients broken down by the different genotypes of the rs1990760 polymorphism are shown in Table 2. Age, age at T1DM diagnosis, proportion of males, BMI, creatinine levels, serum total cholesterol, triglycerides, HbA1c and presence of DR or DN did not differ statistically among the three genotypes. Interestingly, T1DM patients carrying the A allele showed lower levels of systolic BP as compared to patients homozygous for the G allele (A/A: 145.7 ± 23.0 mmHg; P = 0.009). Excluding black patients from the T1DM sample did not change the above mentioned results regarding the association between the analyzed polymorphism and AH. Accordingly, prevalence of AH was lower in T1DM patients carrying the A/A genotype as compared to patients with the G/G genotype (16.1% vs. 45.3%; adjusted residuals P < 0.010). The association of the A/A genotype with protection to AH was confirmed after adjustment for age, gender, presence of DN and ethnicity (OR = 0.334, 95% CI = 0.180–0.622, P = 0.003). The prevalence of AH was 52.8% in white subjects and 29.4% in black subjects (P = 0.009). Excluding black subjects from the T1DM sample did not change the above mentioned results regarding the association between the analyzed polymorphism and AH.

To investigate the association between the rs1990760 (G/A) polymorphism and systolic and diastolic BP in greater depth, we further analyzed systolic and diastolic BP levels according to different genetic inheritance models: additive, recessive or dominant [30] (Table 3). When taking into account the additive model, both systolic and diastolic BP were lower in A/A genotype carriers as compared to G/G genotype carriers, adjusting for age, gender, ethnicity, presence of DN and treatment for hypertension (systolic BP: \( \beta = -13.972, P = 0.034 \), and diastolic BP: \( \beta = -12.186, P = 0.015 \)). In the same way, when taking into account the dominant model, A allele carriers showed lower levels of both systolic and diastolic BP as compared to G/G genotype carriers, adjusting for age, gender, ethnicity, presence of DN and treatment for hypertension (systolic BP: \( \beta = -15.814, P = 0.019 \), and diastolic BP: \( \beta = -11.771, P = 0.003 \)). Systolic and diastolic BP did not differ statistically among the rs1990760 genotypes under a recessive inheritance model (Table 3).

Accordingly, the prevalence of AH was lower in T1DM patients carrying the A/A genotype as compared to patients with the G/G genotype (16.1% vs. 45.3%; adjusted residuals P < 0.010). The association of the A/A genotype with protection to AH was confirmed after adjustment for age, gender, presence of DN and ethnicity (OR = 0.339 for the A/A genotype, P = 0.019). Taking into account that ADA guidelines suggest that the cutoff for the diagnosis of AH in diabetic patients should be BP levels >130/80 mmHg [34], we reanalyzed our data using these values. In agreement with the results described above, the A/A genotype remained significantly associated with protection to AH under an additive model of inheritance and after adjustment for covariates (OR = 0.334, 95% CI = 0.180–0.622, P = 0.003). The prevalence of AH was 52.8% in white subjects and 29.4% in black subjects (P = 0.009). Excluding black subjects from the T1DM sample did not change the above mentioned results regarding the association between the analyzed polymorphism and AH.

In addition, we analyzed 725 patients with T2DM to know better whether the association of the rs1990760 A allele with systolic and diastolic BP was specific to T1DM or could be observed in a non-autoimmune diabetes context. The frequency of the A allele was 0.49 in this sample, and it did not differ from nondiabetic subjects (P = 0.942). Systolic BP did not differ significantly among T2DM patients broken down by the different genotypes of the rs1990760 polymorphism, adjusting for age, sex, ethnicity, BMI and treatment for hypertension (A/A: 145.7 ± 22.7, G/A: 141.5 ± 23.0, G/G: 144.5 ± 24.2 mmHg; P = 0.755). Diastolic BP in these patients also was similar among the three genotypes and controlling for the same covariates (A/A: 85.6 ± 12.9, G/A: 85.3 ± 13.9, G/G: 86.1 ± 14.1 mmHg; P = 0.800) (Table S1 in File S1). Accordingly, prevalence of

---

**Table 1.** Genotype and allele frequencies of the IFIH1 rs1990760 G/A polymorphism in patients with type 1 diabetes mellitus (T1DM) and nondiabetic subjects.

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P1 |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/G      | 114 (21.6%)           | 139 (26.9%)                  | 0.139         | 1                      |
| G/A      | 263 (49.9%)           | 239 (46.2%)                  |               | 1.403 (0.989–1.991)/0.058 |
| A/A      | 150 (28.5%)           | 139 (26.9%)                  |               | 1.453 (0.983–2.147)/0.061 |

**Additive model**

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P1 |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/G      | 114 (43.2%)           | 139 (50.0%)                  | 0.133         | 1                      |
| A/A      | 150 (56.8%)           | 139 (50.0%)                  |               | 1.471 (0.989–2.187)/0.056 |

**Recessive model**

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P1 |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/A-G/G  | 377 (71.5%)           | 378 (73.1%)                  | 0.617         | 1                      |
| A/A      | 150 (28.5%)           | 139 (26.9%)                  |               | 1.157 (0.850–1.575)/0.354 |

**Dominant model**

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P1 |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/G      | 114 (21.6%)           | 139 (26.9%)                  | 0.048         | 1                      |
| A/A      | 413 (78.4%)           | 378 (73.1%)                  |               | 1.421 (1.022–1.975)/0.037 |

Data are presented as number (%) or proportion.

*P values were computed by \( \chi^2 \) tests comparing T1DM patients and nondiabetic subjects.

1Adjusted OR (95% CI) and P values obtained by logistic regression analysis controlling for ethnicity.

doi:10.1371/journal.pone.0083451.e001

---

### Table 2

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/G      | 114 (21.6%)           | 139 (26.9%)                  | 0.139         | 1                      |
| G/A      | 263 (49.9%)           | 239 (46.2%)                  |               | 1.403 (0.989–1.991)/0.058 |
| A/A      | 150 (28.5%)           | 139 (26.9%)                  |               | 1.453 (0.983–2.147)/0.061 |

---

### Table 3

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/G      | 114 (21.6%)           | 139 (26.9%)                  | 0.139         | 1                      |
| G/A      | 263 (49.9%)           | 239 (46.2%)                  |               | 1.403 (0.989–1.991)/0.058 |
| A/A      | 150 (28.5%)           | 139 (26.9%)                  |               | 1.453 (0.983–2.147)/0.061 |

---

### Table S1

| Genotype | T1DM patients (n = 527) | Nondiabetic subjects (n = 517) | Unadjusted P* | Adjusted OR (95% CI)/P |
|----------|------------------------|-------------------------------|---------------|------------------------|
| G/G      | 114 (21.6%)           | 139 (26.9%)                  | 0.139         | 1                      |
| G/A      | 263 (49.9%)           | 239 (46.2%)                  |               | 1.403 (0.989–1.991)/0.058 |
| A/A      | 150 (28.5%)           | 139 (26.9%)                  |               | 1.453 (0.983–2.147)/0.061 |

---

### Table S1 in File S1

Accordingly, prevalence of
AH also did not differ among different genotypes after adjustment for covariates (P = 0.163; Table S1 in File S1).

**IFIH1 Gene Expression in Mononuclear Cells from a Subsample of T1DM Patients**

The median (minimum – maximum values) of IFIH1 mRNA concentrations in mononuclear cell samples from 26 T1DM patients was 6.3 (1.3–7.1) AU. IFIH1 gene expression in this sample did not differ significantly among the three genotypes of the rs11990760 polymorphism [G/G (n = 7): 5.3 (1.4–6.8), G/A (n = 13): 6.6 (1.3–7.1), A/A (n = 7): 1.8 (1.3–6.7) AU; P = 0.274]. Nevertheless, IFIH1 mRNA concentrations were increased in mononuclear cells from T1DM patients with AH (n = 7) as compared with T1DM patients without AH (n = 19) [6.7 (1.7–2.0) vs. 1.8 (1.3–7.0 AU), respectively; P = 0.036; Figure 2].

**Meta-analysis for the association of the IFIH1 rs1990760 polymorphism with T1DM**

The strategy used to identify and select studies for inclusion in the meta-analysis is shown in Figure 1. A total of 7 articles fulfilled the eligibility criteria and were included in the meta-analysis: 6 that had been identified through the database searches [15,16,17,35,36,37] in addition to the case-control study we

**Table 2.** Clinical and laboratory characteristics of patients with type 1 diabetes mellitus, broken down by the different genotypes of the IFIH1 rs1990760 (G/A) polymorphism.

| IFIH1 rs1990760 (G/A) polymorphism | G/G (n = 114) | G/A (n = 263) | A/A (n = 150) | P* |
|-----------------------------------|--------------|--------------|--------------|----|
| Age (years)                       | 36.1 ± 12.6  | 34.9 ± 14.6  | 32.8 ± 12.5  | 0.356 |
| Gender (% male)                   | 51.1         | 50.5         | 56.2         | 0.581 |
| Age of diagnosis (years)          | 19.2 ± 9.9   | 16.5 ± 9.7   | 16.7 ± 11.0  | 0.298 |
| BMI (kg/m²)                       | 22.5 ± 6.5   | 23.8 ± 4.4   | 22.2 ± 4.9   | 0.088 |
| Diabetic nephropathy (%)          | 35.3         | 30.3         | 28.0         | 0.679 |
| Diabetic retinopathy (%)          | 50.0         | 43.7         | 39.4         | 0.352 |
| Systolic blood pressure (mm/Hg)²  | 128.5 ± 18.9 | 121.1 ± 19.0 | 117.41 ± 16.7 | 0.001 |
| Diastolic blood pressure (mm/Hg)³ | 82.4 ± 13.5  | 76.0 ± 10.8  | 74.4 ± 9.8   | 1 × 10⁻¹⁰ |
| Arterial hypertension (%)*        | 45.3         | 33.8         | 16.1         | 1 × 10⁻¹⁰ |
| Triglycerides (mmol/L)            | 0.86 (0.93–1.48) | 0.94 (1.08–1.46) | 0.84 (0.90–1.98) | 0.248 |
| Creatinine (μmol/L)               | 88.4 (97.2–185.6) | 88.4 (88.4–123.7) | 79.6 (79.6–114.9) | 0.265 |
| Hba1c (%)                         | 9.0 (75–0.5) | 8.6 (70–0.5) | 9.24 (77–53) | 0.465 |
| HDL cholesterol (mmol/L)          | 1.5 ± 0.6    | 1.5 ± 0.4    | 1.5 ± 0.5    | 0.664 |
| Total cholesterol (mmol/L)        | 4.7 ± 1.2    | 4.8 ± 1.2    | 4.5 ± 1.1    | 0.184 |

Data are expressed as mean ± SD, median (minimum–maximum values), or percentage.

*P-values were obtained by One-Way ANOVA or χ² tests, as appropriate.

n = number of subjects. HbA1c = glicohemoglobin.

Only P values lower than the Bonferroni threshold (P = 0.0038) were considered statistically significant.

Different letters (a,b,c) mean that values were significantly different using Tukey’s post hoc test or adjusted-residuals (P < 0.05).

**Table 3.** Systolic and diastolic blood pressure levels in T1DM patients broken down by different inheritance models of the IFIH1 rs1990760 (G/A) polymorphism.

| Models | Systolic BP | Unadjusted P* | Beta/adjusted P| Diastolic BP | Unadjusted P* | Beta/adjusted P |
|--------|-------------|---------------|----------------|--------------|---------------|----------------|
| Additive model | | | | | | |
| G/G | 128.5 ± 18.9 | 1 × 10⁻¹⁰ | −14.38/0.034 | 82.4 ± 13.5 | 1 × 10⁻¹⁰ | −12.52/0.013 |
| A/A | 117.4 ± 16.7 | | 74.4 ± 9.8 | | | |
| Recessive model | | | | | | |
| G/A-G/G | 123.5 ± 19.2 | 0.007 | −2.271/0.717 | 79.4 ± 11.9 | 1 × 10⁻¹⁰ | −3.512/0.361 |
| A/A | 117.4 ± 16.7 | | 74.4 ± 9.8 | | | |
| Dominant model | | | | | | |
| G/G | 128.5 ± 18.9 | 1 × 10⁻¹⁰ | −15.649/0.019 | 82.4 ± 13.5 | 1 × 10⁻¹⁰ | −12.15/0.003 |
| G/A-A/A | 119.7 ± 18.2 | | 76.6 ± 10.6 | | | |

Data are expressed as mean ± SD.

*P-values were obtained by Student’s t-test.

P values were computed using logistic regression analysis and are adjusted for age, gender, ethnicity, presence of diabetic nephropathy and treatment for hypertension.

doi:10.1371/journal.pone.0083451.t002

doi:10.1371/journal.pone.0083451.t003
describe above, which was also included in the analysis. NOS scale was used to assess the quality of the studies. In general, most of the studies included in our meta-analysis were considered as having a moderate quality (more than five stars) regarding selection, comparability and exposure. Only one study scored less than four stars.

Table S2 in File S1 lists the genotype and allele distributions and OR (95% CI) for the IFIH1 rs1990760 polymorphism in case and control samples from the different studies reviewed. Table S3 in File S1 summarizes the results of the pooled analyses for association between the IFIH1 polymorphism and susceptibility to T1DM. Our results revealed significant associations between the rs1990760 A allele and risk for T1DM for all analyzed inheritance models: allele contrast (OR = 1.190, 95% CI = 1.160–1.230; Figure 3) dominant (OR = 1.260, 95% CI = 1.184–1.342), recessive (OR = 1.236, 95% CI = 1.180–1.294), and additive (OR = 1.404, 95% CI = 1.310–1.505) models. No significant publication bias was detected for any of the inheritance models assessed for the IFIH1 rs1990760 polymorphism (data not show), which suggests that our data are statistically robust.

Discussion

In response to viral infections, the CARD domain of IFIH1 receptor associate with the CARD-containing adaptor molecule known as IPS-1 (IFN promoter stimulator-1), activating the transcription factors NF-kB and IRF-3, which then cooperate in induction of antiviral IFN-I response [12,13,38]. This local inflammation coupled with triggering of antiviral defenses will in most cases eradicate the viral infection. However, in some genetically susceptible subjects, these cellular attempts to eradicate the infection might go wrong; thus, predisposing for T1DM developing [11].

An association between the IFIH1 gene and T1DM was first reported by Smyth et al. [35], who performed a genome-wide association scan in European families with T1DM. Several polymorphisms located within the IFIH1 gene region showed an association with T1DM, with the rs1990760 polymorphism being the most strongly associated with the disease (OR = 0.86, P = 1.4×10^{-10} for the G allele). This association between the rs1990760 polymorphism and T1DM was replicated in other populations [15,16,36,39], and a recent meta-analysis provided additional evidence for an influence of the A allele on T1DM risk in Europeans [40]. In the present study, we were able to replicate the reported association between the rs1990760 A allele and risk for T1DM with a case-control study followed by a meta-analysis of the literature on the subject.

The exact mechanisms by which IFIH1 polymorphisms contribute to T1DM pathogenesis remain to be explored. The rs1990760 polymorphism is not located in any functional region of the IFIH1 receptor, but the G allele is highly conserved among mammals and may have other, yet-unknown functions or may affect active domains through effects on the tertiary structure. Liu et al. [16] reported that the G/G genotype of this polymorphism was associated with 1.2–2.0 fold-increase in IFIH1 gene expression in mononuclear cells of 374 subjects. Although our present data showed that IFIH1 expression is 3.5 fold higher in mononuclear cells from T1DM patients carrying the G/G genotype when compared with A/A genotype patients, this difference did not reach formal statistical significance probably due to the small sample size analyzed. McCartney et al. [41] reported that optimal functioning of IFIH1 and prompt IFN-I response are required to
prevent diabetes in C57BL/6 mice infected with encephalomyocarditis virus strain D, which has tropism for pancreatic beta-cells. Taking these data into consideration, we therefore hypothesize that probably due to a lower IFIH1 expression, A/A genotype carriers might have a suboptimal IFIH1 function and, consequently, might be more predisposed to develop T1DM.

Our present results showed that age, age at T1DM diagnosis, proportion of males, BMI, creatinine levels, lipid profile, HbA1c and presence of DR or DN did not differ among the three genotypes of the rs1990760 polymorphism. Surprisingly, we observed that T1DM patients carrying the A allele had lower levels of both systolic and diastolic BP as compared to patients with the G/G genotype under additive and dominant models of inheritance. The A/A genotype seems to be associated with significant protection for AH. To our knowledge, this is the first time that an IFIH1 polymorphism is reported as being probably associated with AH.

Hypertension is a common disorder with uncertain etiology [42]. However, in the last years, it has become evident that components of both the innate and adaptive immune systems play an important role in hypertension [42,43,44]. For example, in mice lacking vascular macrophages, angiotensin-II and deoxycorticosterone acetate-salt treatment are unable to raise BP [45,46], corroborating the role of innate immunity in hypertension. Therefore, taking into account the role of low-grade inflammation in the pathogenesis of hypertension [42,44,47,48,49], our present results suggesting an association between the rs1990760 A allele and protection for AH seem to be biologically plausible albeit not yet completely understood.

Recently, Chatterjee et al. [50,51] demonstrated that all the three dsRNAs receptors, TLR-3, RIG-I and IFIH1, are activated in placentas of mice and women with preclampsia (PE), a pregnancy-specific syndrome characterized by excessive maternal immune system activation, inflammation, and endothelial dysfunction, causing hypertension. Chatterjee et al. [50] also showed that treatment of mice with intracellular synthetic dsRNA (PIC) significantly increased TLR3 levels and caused pregnancy-dependent hypertension, endothelial dysfunction and placental inflammation. Our results suggesting that IFIH1 gene expression is increased in mononuclear cell from T1DM patients with AH is in agreement with the data of Chatterjee et al. [50,51] indicating that high expression of dsRNA receptors may have a role in hypertension. Therefore, it seems reasonable to suggest that T1DM patients carrying the A/A genotype may have a lower risk for developing AH due to a decreased IFIH1 gene expression and, consequently, a lesser inflammatory environment.

Our data indicating that the IFIH1 rs1990760 polymorphism is possibly associated with AH in T1DM patients but not in patients with T2DM may be suggestive that the role of this gene in hypertension is dependent of an immune attack as occurring in the development of T1DM or PE. Another possibility is that in T2DM, AH would be more influenced by age, obesity, and insulin resistance than by genetic polymorphism related to inflammation. Consequently, in this group of patients, the effect of the rs1990760 polymorphism in AH would be less important than in the T1DM population. Further studies are needed to confirm the association of the rs1990760 polymorphism with protection for AH in other populations and to evaluate which ligand activates the IFIH1

Figure 3. Forest plot showing individual and pooled ORs (95% CI) for the association between the IFIH1 rs1990760 polymorphism and type 1 diabetes mellitus under an additive inheritance model. The areas of the squares reflect the weight of each individual study and the diamond illustrates the fixed-effect model summary OR (95% CI). a = Europeans, b = Caucasian, c = Asian, d = mixed population. doi:10.1371/journal.pone.0083451.g003
receptor and how increased levels of this dsRNA receptor lead to AH.

In conclusion, our results confirm the association between the A allele of the IFIH1 rs1990760 polymorphism and T1DM in our population and in a meta-analysis of the literature on the subject. Moreover, the A allele seems to be associated with a protection for AH in T1DM patients. This study adds a new possible role of IFIH1 in the pathogenesis of AH in T1DM patients.

Supporting Information

File S1 Supporting tables. Table S1, Clinical and laboratory characteristics of patients with type 2 diabetes mellitus, broken down by the different genotypes of the IFIH1 rs1990760 (G/A) polymorphism. Table S2, Genotype and allele distributions of the IFIH1 rs1990760 polymorphism in patients with type 1 diabetes mellitus (cases) and nondiabetic subjects (controls) for each individual study included in the meta-analysis. Table S3, Pooled measures for associations between the IFIH1 rs1990760 polymorphism and susceptibility for type 1 diabetes mellitus, under different inheritance models. (DOC)

References

1. American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes care 36 Suppl 1: S67–74.
2. Pirot P, Cardozo AK, Eizirik DL (2008) Mediators and mechanisms of pancreatic beta-cell death in type 1 diabetes. Annu Bras Endocrinol Metabol 52: 156–163.
3. Knip M, Veijola R, Virtanen SM, Hyyton H, Vaarala O, et al. (2005) Environmental triggers and determinants of type 1 diabetes. Diabetes 54: 125–136.
4. Seck A, Rewers M (2011) Genetics of type 1 diabetes. Clin Chem 57: 176–185.
5. Jairde Sauter, Sane Goffard, Gharbi, et al. (2010) Enteroviruses and type 1 diabetes: towards a better understanding of the relationship. Rev Med Virol 20: 263–290.
6. Hober Sane, Jairde Racwed, Goffard, et al. (2012) Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxackievirus-B in the pathogenesis of type 1 diabetes. Clin Exp Immunol 47: 51–59.
7. Filippi C, von Herrath M (2000) Viral trigger for type 1 diabetes: pros and cons. Diabetes 59: 2693–2671.
8. Yoon J, Austin M, Ondera T, Notkins A (1997) Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 300: 1173–1179.
9. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, et al. (2007) Coxackie B6 virus infection of β cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 104: 5115–5120.
10. Eldhagani A, Olsson A, Westman J, Tuuven T, Korsgren O, et al. (2007) Effects on isolated human pancreatic islet cells after infection with strains of enterovirus isolated at clinical presentation of type 1 diabetes. Virus Res 128: 47–51.
11. Eizirik DL, Coll MB, Oris F (2009) The role of inflammation in insulin and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 5: 219–226.
12. Kumar H, Kawal T, Akira S (2009) Pathogen recognition in the innate immune response. Biochem J 420: 1–16.
13. Wilkins C, Gale MJ (2010) Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 22.
14. Randall RE, Goodburn S (2008) Interferons and viruses: an interplay between the interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes in both the high-incidence Finnish and the medium-incidence Hungarian populations. Diabetologia 53: 98–102.
15. Schulte BM, Bakkers J, Lanke KHW, Melchers WJG, Westerlaken C, et al. (2010) The interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes in both the high-incidence Finnish and the medium-incidence Hungarian populations. Diabetologia 53: 98–102.
16. Jermendy A, Szatmari I, Laine AP, Lukacs K, Horvath KH, et al. (2010) The interferon-induced helicase IFIH1 Ala946Thr polymorphism is associated with type 1 diabetes and HLA DRB1*0401 in the Hungarian type 1 diabetics. Diabetologia 53: 98–102.
17. Chialiali, DA (2010) Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol 23: 99–104.
18. Concannon P, Onengut-Gumuscu S, Todd JA, Smyth DJ, Pociot F, et al. (2008) A human type 1 diabetes susceptibility locus maps to chromosome 21q22-3. Diabetes 57: 2838–2841.
19. Cen H, Wang W, Leng RX, Wang TY, Pan HF, et al. (2013) Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: A meta-analysis. Autoimmunity 46: 455–462.
20. Pirot P, Cardozo AK, Eizirik DL (2008) Mediators and mechanisms of pancreatic beta-cell death in type 1 diabetes. Annu Bras Endocrinol Metabol 52: 156–163.
21. Knip M, Veijola R, Virtanen SM, Hyyton H, Vaarala O, et al. (2005) Environmental triggers and determinants of type 1 diabetes. Diabetes 54: 125–136.
22. Yang H, Wang Z, Xu K, Gu R, Chen H, et al. (2012) IFIH1 gene
23. Cen H, Wang W, Leng RX, Wang TY, Pan HF, et al. (2013) Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: A meta-analysis. Autoimmunity 46: 455–462.
24. Cumming JL, Sara GM, Wendland AE, Gross JL, de Azevedo MJ (2008) Agreement of different immunoassays for urinary albumin measurement. Clin Chem 54: 925–927.
25. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611–622.
26. Higuchi R, Fockler C, Dollinger G, Watson R (1993) Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y) 11: 1026–1030.
27. Applied Biosystems (2004) Relative Quantitation of Gene Expression Experimental Design and Analysis: Relative Standard Curve Method and Comparative ct Method (DeltaDelta ct). Guide to Performing Relative Quantitation of Gene Expression Using Real-time Quantitative PCR.
28. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264–269, W264.
29. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008–2012.
30. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Available: http://www.medicine.mcgill.ca/rtamblyn/Readings/
31. Minelli, C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34: 1319–1328.
32. Zintzaras E, Lau J (2008) Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61: 634–645.
33. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1550.
34. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2005) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
35. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
36. American Diabetes Association (2010) Standards of Medical Care in Diabetes—2010. Diabetes Care 33: S11–S61.
37. Smyth DJ, Cooper JD, Bailey R, Field S, Barreño O, et al. (2006) A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Hum Genet 119: 617–619.
38. Cen H, Wang W, Leng RX, Wang TY, Pan HF, et al. (2013) Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: A meta-analysis. Autoimmunity 46: 455–462.
39. Cumming JL, Sara GM, Wendland AE, Gross JL, de Azevedo MJ (2008) Agreement of different immunoassays for urinary albumin measurement. Clin Chem 54: 925–927.
40. Cen H, Wang W, Leng RX, Wang TY, Pan HF, et al. (2013) Association of IFIH1 rs1990760 polymorphism with susceptibility to type 1 diabetes mellitus, under different inheritance models. (DOC)

Acknowledgments

The authors acknowledge Dr. Cristiane B. Leita˜o, Dr. Ticiana C. Rodrigues and Dr. Måikel Coll for the suggestions made to improve the manuscript, and Mr. Guilherme C. K. Duarte for collecting data for the meta-analysis.

Author Contributions

Conceived and designed the experiments: AB DC. Performed the experiments: AB FSOL NEL BMS. Analyzed the data: AB FSOL LAB NEL NHC DC BMS. Contributed reagents/materials/analysis tools: NHC DC. Wrote the paper: AB DC. Contributed to the discussion and reviewed the final version of the manuscript: FSOL LAB NEL NHC BMS.
41. McCartney SA, Vermi W, Lonardi S, Rossini C, Otero K, et al. (2011) RNA sensor-induced type I IFN prevents diabetes caused by a beta cell-tropic virus in mice. J Clin Invest 121: 1497–1507.

42. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, et al. (2011) Inflammation, immunity, and hypertension. Hypertension 57: 132–140.

43. Verlohren S, Müller DN, Luft FC, Dechend R (2009) Immunology in hypertension, preeclampsia, and target-organ damage. Hypertension 54: 439–443.

44. Schiffrin EL (2010) T lymphocytes: a role in hypertension? Curr Opin Nephrol Hypertens 19: 181–186.

45. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, et al. (2005) Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 25: 2106–2113.

46. Ko EA, Amiri F, Pandey NR, Javeshghani D, Leibovitz E, et al. (2007) Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice. Am J Physiol Heart Circ Physiol 292: H1789–1795.

47. White FN, Grollman A (1964) Autoimmune Factors Associated with Infarction of the Kidney. Nephron 1: 93–102.

48. Leibowitz A, Schiffrin EL (2011) Immune mechanisms in hypertension. Curr Hypertens Rep 13: 463–472.

49. Luft FC, Dechend R, Müller DN (2012) Immune mechanisms in angiotensin II-induced target-organ damage. Ann Med 44 Suppl 1: S49–54.

50. Chatterjee P, Weaver LE, Doesch KM, Kopriva SE, Chiasson VL, et al. (2012) Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS One 7: e41884.

51. Chatterjee P, Weaver LE, Chiasson VL, Young KJ, Mitchell BM (2011) Do double-stranded RNA receptors play a role in preeclampsia? Placenta 32: 201–205.